Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want
Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field's broadest ...
May 5, 2026 09:25 AM EDTUpdated 01:08 PM DealsPharma Updated: Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want Kyle LaHucik Biotech Correspondent Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that